TreatMD.com offers telemedicine without borders

TreatMD.com Beta has been introduced as telemedicine that can reach across national borders, so it can treat patients regardless of location.

TreatMD’s international platform opens up new possibilities for both patients and clinicians juggling office visits, in-home visits, insurance reimbursement, E-Prescribing, health devices and monitoring.

Currently, TreatMD has integrated itself into being used in all 50 states by more than 500 healthcare providers and 22 international countries. The software is available in more than 30 languages.

"We looked at many office scheduling companies, house visits, and all these new Telehealth companies stirring up the past couple years, and we just wanted to build something special and provide a new patient and provider presentation for it all. We think we have created the most comprehensive and interactive marketplace for Telemedicine on a global scale," said TreatMD.com co-founder Bryan Lenett.

The service offers a free premium membership to providers to start offering care as soon as possible. Once on the site, providers can register, set consultation rates, create schedules and get to work within minutes.

On the other side of TreatMD.com, patients can search for providers based on their location, seek out specialists and read reviews on providers. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.